Renal denervation stutters with shock Medtronic trial failure
This article was originally published in Clinica
Executive Summary
Could the “next big thing” in medtech already be set for the scrap heap? Medtronic has just reported that the US pivotal trial of its Symplicity renal denervation device has not met its primary efficacy endpoint, scuppering its chances of FDA approval and sending the firm’s stock down 5% in morning trading.
You may also be interested in...
EuroPCR 2018: Medtronic RDN Rises Out Of Ashes With Positive SPYRAL Data
Medtronic looks to be back on track with its renal denervation plans, after announcing its Symplicity Spyral system got off to a good start with positive six-month results in the SPYRAL HTN-ON MED pilot study. The data, presented at EuroPCR 2018 in Paris, showed that Symplicity Spyral was able to reduce blood pressure significantly in hypertensive patients prescribed anti-hypertension medications, with no major adverse safety events out to six months.
Starts & Stops: Medtronic's Symplicity Flatlines For Heart Failure
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions over the last month. This edition, which looks at trial updates from Sept. 8 through to Oct. 7, throws the spotlight on four studies that had the plug pulled, including Medtronic's Symplicity-HF trial.
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.